Relay Therapeutics, Inc.
RLAYHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeHeadquartered within the healthcare sector, Relay Therapeutics, Inc. focuses on Biotechnology services and products. Relay Therapeutics, Inc. operates as a clinical-stage precision medicines company. The $3.03B market capitalization puts RLAY squarely in mid-cap range for its industry. It transforms the drug discovery process with a focus on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications.
Market Cap
$3.03B
Beta
1.75
P/E (TTM)
—
P/E (Fwd)
-8.32
EPS (TTM)
$-1.56
EPS (Fwd)
$-1.67
ROE
-40.0%
ROA
-24.7%
Cash
$642.1M
Total Debt
$31.6M
Free CF
-$121.2M
52W Change
363.3%
Annual Financials
Cash vs Debt
With $642.1M in cash and $31.6M in debt, RLAY maintains more liquidity than leverage. This favorable balance sheet position can be an asset when capital markets become less accommodating. The company is burning cash, with free cash flow at -$121.2M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. ROE of -40.0% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. Revenue has grown from $1.4M (2022) to $15.4M (2025), reflecting a 1012% increase over the period.
A beta of 1.75 means RLAY is more volatile than average. Investors should be prepared for wider price swings relative to broader indices. With cash comfortably exceeding debt, RLAY has financial flexibility that may help navigate uncertain periods. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for Relay Therapeutics, Inc. and its sector.